Zealand announces an amendment to its Articles of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants

Copenhagen, 2015-04-13 16:29 CEST (GLOBE NEWSWIRE) -- 13 April 2015  ─ Zealand Pharma (“Zealand”) (Nasdaq Copenhagen: ZEAL) announces an amendment to its Articles of Association to reflect an increase in the company’s share capital following exercise of employee warrants as announced in Company Announcement no. 14/2015 on 11 April 2015.

The share capital has been increased by nominal DKK 106,220 to nominal DKK 23,420,100 divided into 23,420,100 shares with a nominal value of DKK 1 each.

The amendment of Zealand’s Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority. The new Articles of Association are attached to this announcement and are also available on the company’s website: www.zealandpharma.com .                              

  ●●●●●

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President for Communications and Investor Relations

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a pipeline of novel wholly-owned medicines alongside a partnered product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia ® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory submission of Lyxumia ® is planned for Q3 2015 and US/EU regulatory submissions for LixiLan in Q4 2015.

Zealand’s wholly-owned products include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) in Phase I as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.

For further information: www.zealandpharma.com            Follow us on Twitter @ZealandPharma

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 190

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 423

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 376

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 355

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 126

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 253

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 313

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 271

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 342

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

Viatris Launches Cash Tender Offers for Outstanding Notes

Updated Category News Views 56

Viatris Launches Cash Tender Offers for Outstanding Notes Viatris Inc. (NASDAQ: VTRS), a leading player in the global healthcare sector, has initiated tender offers to acquire certain outstanding notes. This move is designed to strengthen its financial framework and enhance returns for its shareholders. Notably, the offers include various senior notes that were originally...

Continue Reading
Coke Florida Launches Joyful Holiday Caravan Across Florida

Updated Category News Views 239

Coke Florida Kicks Off Holiday Spirit with Caravan Tour Coca-Cola Beverages Florida, LLC (Coke Florida) is thrilled to share that its beloved annual "Holiday Caravan" is set to return. This event, which has become an essential part of the holiday season, features the iconic Coca-Cola red delivery truck decked out in festive cheer. Families will enjoy complimentary samples...

Continue Reading
Nexxen to Join RBC Conference, Share Insights on Technology

Updated Category News Views 68

Nexxen's Upcoming Participation at RBC Global Conference Nexxen International Ltd. (AIM/NASDAQ: NEXN), a leading global advertising technology platform, is geared up to take part in a significant event, the RBC Global Technology, Internet, Media and Telecommunications Conference. This event provides a stellar opportunity for companies to connect with investors and share...

Continue Reading
GayVeterans.us Obtains 501(c)(3) Status to Broaden Support

Updated Category News Views 125

GayVeterans.us Achieves 501(c)(3) Tax Exempt Status GayVeteransUS-Inc. has recently been granted 501(c)(3) tax-exempt status, marking a significant milestone for the organization. This designation enables supporters to make tax-deductible contributions, strengthening the community's ability to provide enhanced resources and support. The dedication of veteran volunteers...

Continue Reading
Virbac Expands Portfolio with Acquisition of Felanorm Solution

Updated Category News Views 130

Virbac Enhances Its Offerings with Felanorm Acquisition Virbac has announced a significant acquisition that marks a pivotal moment in its commitment to improving the health and quality of life for senior cats. This globally recognized drug is aimed at treating feline hyperthyroidism, a condition that is becoming increasingly common in older cats. Understanding Feline...

Continue Reading